Bioventus this week said it appointed Ken Reali as CEO, effective April 20.
Reali will replace Tony Biel who is retiring on April 30.
“I am honored to have the opportunity to lead Bioventus,” Reali said in a news release. “The company’s broad product portfolio, global presence and solid growth have it well-positioned to serve the needs of patients and physicians. Even more successes lie ahead and I’m excited to work with the talented Bioventus team to drive strong value for all stakeholders.”
Prior to joining the company Reali was president and CEO of Clinical Innovations. He has also held numerous leadership positions at Biomet, Stryker, Smith & Nephew and currently serves on the boards of Ossio Integrative Orthopedics, AdvaMed and AdvaMed Accell.
“Tony has been an outstanding CEO and leader of Bioventus and we will miss him, though at the same time, the board and I are pleased to welcome Ken Reali as the incoming CEO of Bioventus,” Bioventus board chairman William Hawkins said. “Ken’s experience in business development, driving top and bottom-line growth while building a compliant culture, global product commercialization and sales of medical devices, combined with a strong background in ethics and compliance, market analysis, experience as a CEO in both public and private companies is just the right fit to lead Bioventus.”
